BJU Int July 2013 PMID 23490404

Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(®) ) or abobotulinumtoxinA (Dysport(®) ) make a difference?

Pravisha Ravindra, Benjamin L Jackson, Richard J Parkinson

Download social card

Mentions

Peak: 2 in Oct 2019

across 2 sources since Jun 2013

Extended reach

3,663

potential audience

Total likes

Video views

1,290

Mentions per month

Jun 2013 – Oct 2019

Where it's discussed

X / Twitter2 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions focus on raising awareness about the differences between botulinum toxin types, with phrases like 'be careful about dosing' and references to lessons learned by urologists, which indicate a practical and cautious tone. This reflects moderate engagement and perceived impact, emphasizing safety considerations over detailed critique.

AgreementModerate agreement

Most discussions acknowledge the key findings of the publication, emphasizing the differences between Botox and Dysport and their risks, indicating general agreement with the study.

InterestModerate interest

The discussions show moderate interest by highlighting practical implications, such as dosing considerations and patient safety, rather than deep scientific debate.

EngagementNeutral engagement

Overall, the conversations are somewhat superficial, mainly sharing awareness and cautionary notes without extensive analysis or new insights.

ImpactModerate impact

The topics discussed could influence clinical awareness and practice slightly, especially regarding dosing and safety, suggesting a moderate impact.

Abstract in brief

The study compared two types of botulinum toxin (Botox and Dysport) used to treat nonneurogenic overactive bladder and found similar improvements in symptoms like urinary frequency and incontinence, with no difference in how long the effects lasted.
The researchers observed that patients treated with Dysport had nearly double the rate of urinary retention requiring catheterization compared to those treated with Botox.
Overall, the study suggests that these two botulinum toxins are not interchangeable at the doses used, mainly because Dysport has a higher risk of causing urinary retention.]

Read the full abstract

All mentions

Comparison of Botulinum Toxins for Non-Neurogenic Overactive Bladder Treatment

This study compares Botox and Dysport for treating nonneurogenic overactive bladder, finding similar symptom improvements but higher urinary retention risk with Dysport.

BJUI · Jun 28, 2013 1,290 views

SFUPA

@SFUPA1 · X

RT @YPedUrolClub: Are you aware not all botulinum A is the same? Be careful about dosing with the different agents. Lessons we can learn fr…

Oct 10, 2019 · 1 share · 879 followers View post →

Young Pediatric Urologists Club

@YPedUrolClub · X

Are you aware not all botulinum A is the same? Be careful about dosing with the different agents. Lessons we can learn from adult #urologists, #pedsurology https://t.co/iWQHdnocW7

Oct 9, 2019 · 4 likes · 1 share · 1,490 followers View post →